The US Food and Drug Administration (USFDA) has classified Zydus Lifesciences’ Jarod injectables manufacturing facility as ‘official action indicated’ (OAI), following an inspection. USFDA conducted inspection at the injectables manufacturing facility between April 15 and April 23, 2024.
As per the USFDA, OAI implies that the regulator may withhold approval of any pending product applications or supplements filed from such facility till the outstanding observations related to non compliance of manufacturing norms laid down by it.
The company will work closely with the agency to resolve the regulatory status of this facility expeditiously.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1924.05 |
| Dr. Reddys Labs. | 1234.60 |
| Cipla | 1426.80 |
| Zydus Lifesciences | 1131.05 |
| Lupin | 2497.75 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: